Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01341054
Other study ID # uspchamomilla01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2011
Est. completion date August 2011

Study information

Verified date May 2023
Source University of Sao Paulo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine the Chamomilla recutita solution dose needed to reduce the intensity and evolution time of oral mucositis in adult subjects submitted to HSCT.


Description:

Population: adult subjects, submitted to hematopoietic stem cell transplantation (HSCT) at a cancer hospital in the interior of São Paulo State. The following inclusion criteria were adopted for sample selection purposes: subjects over 18 years of age, candidates for allogeneic HSCT and with intact oral cavity on the first day of conditioning. Subjects will be excluded if they present any adverse reaction to the active principles of Chamomilla recutita; receive oral or intravenous anticoagulation therapy; use oral or systemic topical anti-inflammatory medication; receive any other type of intervention for mucositis not included in the standard oral care protocol.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date August 2011
Est. primary completion date August 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - subjects over 18 years of age; - candidates for allogeneic HSCT; - with intact oral cavity on the first day of conditioning. Exclusion Criteria: - present any adverse reaction to the active principles of Chamomilla recutita; - receive oral or intravenous anticoagulation therapy; - use oral or systemic topical anti-inflammatory medication; - receive any other type of intervention for mucositis not included in the standard oral care protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
mouthwash with Chamomilla
The Chamomile recutita mouthwash was administered two times daily for 30 days. 10 mL of this solution was swished around in the mouth for approximately one minute and then expectorated.
Standard oral care protocol
The standard protocol at the unit, which comprises mouthwash with chlorhexidine 0,12% twice a day; oral hygiene teaching, recommended at least three times per day and always after meals. For brushing, brushes with extra-soft bristles and non-abrasive toothpaste are used. In case the toothbrush cannot be used due to gingival or oral mucosa bleeding, gauze is used to replace it.

Locations

Country Name City State
Brazil Hospital Amaral Carvalho Jau São Paulo

Sponsors (1)

Lead Sponsor Collaborator
University of Sao Paulo

Country where clinical trial is conducted

Brazil, 

References & Publications (1)

Braga FT, Santos AC, Bueno PC, Silveira RC, Santos CB, Bastos JK, Carvalho EC. Use of Chamomilla recutita in the Prevention and Treatment of Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Randomized, Controlled, Phase II Clinical Trial. Cancer Nurs. 2015 Jul-Aug;38(4):322-9. doi: 10.1097/NCC.0000000000000194. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Oral mucositis intensity The measurement will be held on the first day of the conditioning regimen to bone marrow grafting. In an expected average of 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT02252926 - Local Anesthetic Treatment of Oral Pain in Patients With Mucositis Phase 2
Completed NCT01155609 - L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer N/A
Completed NCT00357942 - Topical Morphine for Stomatitis-related Pain Induced by Chemotherapy Phase 4
Completed NCT00360685 - Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX N/A
Completed NCT04586491 - The Effect of Oral Care Protocol on Prevention of Oral Mucositis in Pediatric Cancer Patients N/A
Withdrawn NCT02589860 - Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
Not yet recruiting NCT02506231 - The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome Phase 2/Phase 3
Completed NCT02639377 - Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis and Gingivitis Phase 2
Completed NCT02605382 - Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis Phase 2
Completed NCT00956254 - Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis Phase 3
Terminated NCT02575313 - The Effects of Whole Food Intervention on Mucositis in Patients Treated for Head and Neck Cancer Phase 1/Phase 2
Completed NCT00584597 - A Trial of Homeopathic Medication TRAUMEEL S for the Treatment of Radiation-Induced Mucositis Phase 1
Enrolling by invitation NCT05590117 - Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer Early Phase 1
Completed NCT05635929 - Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients. N/A
Completed NCT05181943 - Effectiveness of Photo-biomodulation in the Treatment of Chemotherapy Induced Mucositis N/A
Completed NCT03713567 - Clinical, Immunological and Microbiological Evaluation of Experimental Gingivitis and Peri-implant Mucositis N/A
Completed NCT02671812 - Outcome After Dental Implant Treatment
Terminated NCT02273752 - Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Phase 2
Recruiting NCT01707641 - Effect of Lactobacillus Brevis CD2 in Prevention of Radio-chemotherapy Induced Oral Mucositis in Head and Neck Cancer Phase 4
Completed NCT01015183 - Prevention Chemotherapy Induced Mucositis by Zinc Sulfate Phase 2/Phase 3

External Links